BR112018010006A2 - sistema de expressão de gene, vetor, método para produção de uma célula-tronco pluripotente induzida e para tratamento de câncer, vacina, e, composição terapêutica. - Google Patents

sistema de expressão de gene, vetor, método para produção de uma célula-tronco pluripotente induzida e para tratamento de câncer, vacina, e, composição terapêutica.

Info

Publication number
BR112018010006A2
BR112018010006A2 BR112018010006A BR112018010006A BR112018010006A2 BR 112018010006 A2 BR112018010006 A2 BR 112018010006A2 BR 112018010006 A BR112018010006 A BR 112018010006A BR 112018010006 A BR112018010006 A BR 112018010006A BR 112018010006 A2 BR112018010006 A2 BR 112018010006A2
Authority
BR
Brazil
Prior art keywords
gene expression
expression system
induced pluripotent
vaccine
vector
Prior art date
Application number
BR112018010006A
Other languages
English (en)
Inventor
E Wagner Thomas
Original Assignee
Orbis Health Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbis Health Solutions Llc filed Critical Orbis Health Solutions Llc
Publication of BR112018010006A2 publication Critical patent/BR112018010006A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

a presente invenção se refere geralmente a um sistema de expressão de gene que utiliza um replicon de alfavírus e promotor t7. o sistema é capaz de expressar proteínas no citoplasma da célula sem integrar o gene de interesse no genoma de uma célula hospedeira. a invenção tem uma ampla gama de aplicações como produção de células pluripotentes induzidas e vacinas contra patógenos e cânceres.
BR112018010006A 2015-11-18 2016-11-18 sistema de expressão de gene, vetor, método para produção de uma célula-tronco pluripotente induzida e para tratamento de câncer, vacina, e, composição terapêutica. BR112018010006A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562256788P 2015-11-18 2015-11-18
PCT/US2016/062703 WO2017087763A1 (en) 2015-11-18 2016-11-18 T7 alpha viral vector system

Publications (1)

Publication Number Publication Date
BR112018010006A2 true BR112018010006A2 (pt) 2019-02-05

Family

ID=58717836

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010006A BR112018010006A2 (pt) 2015-11-18 2016-11-18 sistema de expressão de gene, vetor, método para produção de uma célula-tronco pluripotente induzida e para tratamento de câncer, vacina, e, composição terapêutica.

Country Status (8)

Country Link
US (1) US10801041B2 (pt)
EP (1) EP3377635A4 (pt)
JP (1) JP2019500025A (pt)
AU (1) AU2016355191B2 (pt)
BR (1) BR112018010006A2 (pt)
CA (1) CA3005739A1 (pt)
SG (1) SG11201804197RA (pt)
WO (1) WO2017087763A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3075549A1 (en) * 2017-09-13 2019-03-21 Biontech Rna Pharmaceuticals Gmbh Rna replicon for reprogramming somatic cells
JP2021509122A (ja) 2018-01-02 2021-03-18 クロリス・バイオサイエンシーズ・インコーポレイテッドＫｈｌｏｒｉｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 癌のための予防および治療処置としてのｉｐｓｃベースのワクチン
EP4085130A4 (en) 2019-12-31 2024-04-10 Elixirgen Therapeutics Inc TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
EP0442926A1 (en) 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
US5122457A (en) 1989-10-19 1992-06-16 Schering Corporation Expression systems utilizing bacteriophage t7 promoters, gene sequences, and t7 rna polymerase
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5962318A (en) 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US20030170871A1 (en) 2000-04-25 2003-09-11 Chiron Corporation Alphavirus-based vectors for persistent infection
US7557200B2 (en) 2001-02-01 2009-07-07 Johns Hopkins University Superior molecular vaccine based on self-replicating RNA, suicidal DNA or naked DNA vector, that links antigen with polypeptide that promotes antigen presentation
JP4430868B2 (ja) * 2001-03-30 2010-03-10 ジーエイチシー リサーチ ディベロップメント コーポレイション 単球に特異的な粒子性送達媒体
US20040121165A1 (en) 2002-12-20 2004-06-24 Laird Ronald E. Coated article with reduced color shift at high viewing angles
EP1608762B1 (en) * 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
JP2008530032A (ja) * 2005-02-16 2008-08-07 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 腫瘍治療のためのフラビウイルスレプリコン構築物
EP2208786B1 (en) 2005-12-13 2018-08-01 Kyoto University Nuclear reprogramming factor
EP3399025A1 (en) 2007-03-23 2018-11-07 Wisconsin Alumini Research Foundation Somatic cell reprogramming
WO2008134487A1 (en) * 2007-04-25 2008-11-06 Ghc Research Development Corporation Macrophage transfection method
US10369204B2 (en) * 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US20110250692A1 (en) 2008-10-30 2011-10-13 Kyoto University Method for producing induced pluripotent stem cells
US20120207744A1 (en) 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
MX2012010532A (es) 2010-03-12 2013-02-07 Lipo Chemicals Inc Compuesto, composicion y metodo para proteger la piel de luz visible de alta energia.
AU2011276236B2 (en) * 2010-07-06 2016-03-10 Glaxosmithkline Biologicals S.A. Cationic oil-in-water emulsions
BR112013010288A2 (pt) * 2010-10-27 2016-09-20 Harrisvaccines Inc método de produção de uma vacina para proteger um animal de biótipo de microrganismo, vacina para proteger um animal de um biótipo de microrganismo, método para proteger um animal e método para determinar se um animal foi vacinado
HUE041853T2 (hu) 2012-05-21 2019-05-28 Univ California Humán IPS sejtek elõállítása szintetikus önreplikációra képes RNS segítségével
US9687542B2 (en) * 2012-06-19 2017-06-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Rift valley fever virus replicon particles and use thereof

Also Published As

Publication number Publication date
AU2016355191B2 (en) 2023-06-29
CA3005739A1 (en) 2017-05-26
EP3377635A4 (en) 2019-05-08
WO2017087763A1 (en) 2017-05-26
SG11201804197RA (en) 2018-06-28
US20180371494A1 (en) 2018-12-27
AU2016355191A1 (en) 2018-06-14
JP2019500025A (ja) 2019-01-10
EP3377635A1 (en) 2018-09-26
US10801041B2 (en) 2020-10-13

Similar Documents

Publication Publication Date Title
CR20170174A (es) Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b
BR112017016301A2 (pt) novo promotor e usos do mesmo
BR112018013930A2 (pt) vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2022006513A (es) Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica.
BR112017024115A2 (pt) regulação de expressão genética mediada por nuclease
BR112017006980A2 (pt) imunomoduladores
BR112016017736A2 (pt) métodos e produtos para produção e distribuição de ácido nucleico
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
BR112013027307A2 (pt) método para tratar uma matriz de tecido; matriz de tecido acelular
CL2016003277A1 (es) Métodos para preparar análogos de nucleótido sustituidos
BR112018071221A2 (pt) composições e métodos para programar células terapêuticas usando nanocarreadores de ácido nucleico alvejados
BR112017011582A2 (pt) fibroblasto de embrião de galinha imortalizado, cultura de célula, métodos para preparação de um cef importalizado, para a replicação de um vetor viral aviário e para a preparação de uma vacina, e, vacina.
EP3161138A4 (en) Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
BR112016015187A2 (pt) proteína de fusão para inibição da angiogênese ou do crescimento e uso da mesma
BR112018010006A2 (pt) sistema de expressão de gene, vetor, método para produção de uma célula-tronco pluripotente induzida e para tratamento de câncer, vacina, e, composição terapêutica.
MX370628B (es) Composiciones y metodos para tratar las espinillas.
MX2015007361A (es) Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos.
MX2016008258A (es) Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
BR112015021210B8 (pt) Método para reduzir a expressão de um ácido nucleico alvo em uma planta e ácido nucleico recombinante
BR112019005270A2 (pt) produção heteróloga de ácido 10-metilesteárico
EP3998341A3 (en) Adenoviral vectors
NZ711564A (en) Methods of treating colorectal cancer
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]